Thomas Ochsenkühn
Research Subjects
Thomas Ochsenkühn has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
B. Göke
4 shared publicationsDaniel Szokodi
VIVAQ-MVZ GmbH München, Sonnenstr. 29 80331, München, Deutschland
4 shared publicationsC. Tillack
2 shared publicationsConstanze H. Waggershauser
VIVAQ-MVZ GmbH München, Sonnenstr. 29 80331, München, Deutschland
2 shared publicationsCornelia Tillack
IBD center Munich, Munich, Germany
2 shared publicationsM. Sackmann
2 shared publications
Latest Publications
- 31 October 2025
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 167 (S3) , 55-61
CED: Ein Update für die hausärztlich-internistische Praxis
- 31 October 2025
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 167 (S3) , 55-61
CED: Ein Update für die hausärztlich-internistische Praxis
- Open Access
- 24 August 2022
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2022, 1-9
Impact of Immunotherapies on SARS-CoV-2-Infections and Other Respiratory Tract Infections during the COVID-19 Winter Season in IBD Patients
Background. COVID-19 represents one of the most significant medical problems of our time. Aims. This study is focused on the question whether patients with inflammatory bowel disease (IBD) who receive immunotherapies are more vulnerable to respiratory tract infections and SARS-CoV-2 infections in comparison to medical staff, as a cohort with an increased infection risk, and to the general population in a COVID-19 hotspot. Methods. We analysed data regarding respiratory tract infections that were collected in our IBD registry and compared them with corresponding data from medical employees in our associated Isarklinikum hospital and from the healthy general population in Munich, Germany, over the same time frame in April and June 2020. Patients were tested for SARS-CoV-2 immunoglobulins (Ig). Results. Symptoms of respiratory tract infections occurred equally frequent in IBD patients with immunotherapies as compared to those without. Older age (>49 years), TNF-inhibitor, and ustekinumab treatment showed a significantly protective role in preventing respiratory tract symptomatic COVID-19 infections that occurred in 0.45 of all our 1.091 IBD patients. Of those, 1.8 were positive for SARS-CoV-2 Ig, identically to the general population of Munich with also 1.8 positivity. Whilst more than 3 of all COVID-19 subjects of the general population died during the first wave, none of our IBD patients died or needed referral to the ICU or oxygen treatment. Conclusions. In our study, IBD patients are as susceptible to respiratory tract infections or SARS-CoV-2 as the normal population. There is no evidence of an association between IBD therapies and increased risk of COVID-19. Interestingly, a reduced rate of COVID-19 deaths in IBD patients, the majority on immunomodulator therapy, was observed, compared to the general population. Therefore, no evidence was found to suggest that IBD medication should be withheld, and adherence should be encouraged to prevent flares. In addition to older age (>49 years), TNF inhibitors and ustekinumab show a protective role in preventing respiratory tract infections. In addition, these results add to the growing evidence that supports further investigation of TNF inhibitors as a possible treatment in the early course of severe COVID-19.
- 24 August 2022
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2022, 1-9
Open AccessImpact of Immunotherapies on SARS-CoV-2-Infections and Other Respiratory Tract Infections during the COVID-19 Winter Season in IBD Patients
Background. COVID-19 represents one of the most significant medical problems of our time. Aims. This study is focused on the question whether patients with inflammatory bowel disease (IBD) who receive immunotherapies are more vulnerable to respiratory tract infections and SARS-CoV-2 infections in comparison to medical staff, as a cohort with an increased infection risk, and to the general population in a COVID-19 hotspot. Methods. We analysed data regarding respiratory tract infections that were collected in our IBD registry and compared them with corresponding data from medical employees in our associated Isarklinikum hospital and from the healthy general population in Munich, Germany, over the same time frame in April and June 2020. Patients were tested for SARS-CoV-2 immunoglobulins (Ig). Results. Symptoms of respiratory tract infections occurred equally frequent in IBD patients with immunotherapies as compared to those without. Older age (>49 years), TNF-inhibitor, and ustekinumab treatment showed a significantly protective role in preventing respiratory tract symptomatic COVID-19 infections that occurred in 0.45 of all our 1.091 IBD patients. Of those, 1.8 were positive for SARS-CoV-2 Ig, identically to the general population of Munich with also 1.8 positivity. Whilst more than 3 of all COVID-19 subjects of the general population died during the first wave, none of our IBD patients died or needed referral to the ICU or oxygen treatment. Conclusions. In our study, IBD patients are as susceptible to respiratory tract infections or SARS-CoV-2 as the normal population. There is no evidence of an association between IBD therapies and increased risk of COVID-19. Interestingly, a reduced rate of COVID-19 deaths in IBD patients, the majority on immunomodulator therapy, was observed, compared to the general population. Therefore, no evidence was found to suggest that IBD medication should be withheld, and adherence should be encouraged to prevent flares. In addition to older age (>49 years), TNF inhibitors and ustekinumab show a protective role in preventing respiratory tract infections. In addition, these results add to the growing evidence that supports further investigation of TNF inhibitors as a possible treatment in the early course of severe COVID-19.
- Open Access
- 14 August 2020
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 52 (5) , 898-899
Letter: immunotherapy in IBD patients in a SARS‐CoV‐2 endemic area
LINKED CONTENTThis article is linked to Taxonera et al papers. To view these articles, visit https://doi.org/10.1111/apt.15804 and https://doi.org/10.1111/apt.15955
- 14 August 2020
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 52 (5) , 898-899
Open AccessLetter: immunotherapy in IBD patients in a SARS‐CoV‐2 endemic area
LINKED CONTENTThis article is linked to Taxonera et al papers. To view these articles, visit https://doi.org/10.1111/apt.15804 and https://doi.org/10.1111/apt.15955
- Open Access
- 1 February 2020
- Published by Wiley in United European Gastroenterology Journal
- Vol. 8 (1) , 91-98
Clinical outcomes with ustekinumab as rescue treatment in therapy‐refractory or therapy‐intolerant ulcerative colitis
Background: Recently, ustekinumab a monoclonal antibody targeting interleukin‐12 and −23 and successfully used in Crohn’s disease also has been shown to be effective in induction and maintaining remission in patients with moderate to severe ulcerative colitis in a large phase 3 trial. However, no observational data on the use of ustekinumab in ulcerative colitis in daily clinical practice is available.Aim: The purpose of this study was to assess the clinical outcomes achieved with ustekinumab as rescue treatment in therapy‐refractory or ‐intolerant ulcerative colitis in a real‐life setting.Methods: A retrospective data analysis was performed in 19 ulcerative colitis patients who were intolerant or refractory to all of the following drugs: steroids, purine‐analogues, tumour necrosis factor antibodies and vedolizumab. To all patients ustekinumab was provided as a rescue treatment (intravenous induction with 6 mg/kg, followed by week subcutaneous injection once every eight weeks of 90 mg). The primary outcome was achievement of clinical remission at one year, defined as score of ≤ 3 points in the Lichtiger score (colitis activity index). Patients were evaluated regularly and a colonoscopy was performed before the start and at the end of the observation. Ethical approval was provided by Ethikkommission Ärztekammer Hamburg (PV 5539).Results: In five patients, therapy was stopped due to refractory disease or side effects. In all remaining 14 patients the median colitis activity index dropped from 8.5 points (range 1–12) at start to 2.0 points at one year (range 0–5.5) and Mayo endoscopy scores fell from a median of two points (range 1–3, mean of 2.3) at start to a median of one point (range 1–3, mean of 1.4) at one year. Including the five drop‐outs, clinical remission was achieved in 53% of the 19 patients at one year.Conclusions: In accordance with the UNIFI (A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis) trial our real‐life data support ustekinumab as an effective and safe treatment option in therapy refractory moderate to severe ulcerative colitis with a history of biological therapies.
- 1 February 2020
- Published by Wiley in United European Gastroenterology Journal
- Vol. 8 (1) , 91-98
Open AccessClinical outcomes with ustekinumab as rescue treatment in therapy‐refractory or therapy‐intolerant ulcerative colitis
Background: Recently, ustekinumab a monoclonal antibody targeting interleukin‐12 and −23 and successfully used in Crohn’s disease also has been shown to be effective in induction and maintaining remission in patients with moderate to severe ulcerative colitis in a large phase 3 trial. However, no observational data on the use of ustekinumab in ulcerative colitis in daily clinical practice is available.Aim: The purpose of this study was to assess the clinical outcomes achieved with ustekinumab as rescue treatment in therapy‐refractory or ‐intolerant ulcerative colitis in a real‐life setting.Methods: A retrospective data analysis was performed in 19 ulcerative colitis patients who were intolerant or refractory to all of the following drugs: steroids, purine‐analogues, tumour necrosis factor antibodies and vedolizumab. To all patients ustekinumab was provided as a rescue treatment (intravenous induction with 6 mg/kg, followed by week subcutaneous injection once every eight weeks of 90 mg). The primary outcome was achievement of clinical remission at one year, defined as score of ≤ 3 points in the Lichtiger score (colitis activity index). Patients were evaluated regularly and a colonoscopy was performed before the start and at the end of the observation. Ethical approval was provided by Ethikkommission Ärztekammer Hamburg (PV 5539).Results: In five patients, therapy was stopped due to refractory disease or side effects. In all remaining 14 patients the median colitis activity index dropped from 8.5 points (range 1–12) at start to 2.0 points at one year (range 0–5.5) and Mayo endoscopy scores fell from a median of two points (range 1–3, mean of 2.3) at start to a median of one point (range 1–3, mean of 1.4) at one year. Including the five drop‐outs, clinical remission was achieved in 53% of the 19 patients at one year.Conclusions: In accordance with the UNIFI (A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis) trial our real‐life data support ustekinumab as an effective and safe treatment option in therapy refractory moderate to severe ulcerative colitis with a history of biological therapies.
- 12 November 2019
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 161 (S3) , 52-60
Chronisch entzündliche Darmerkrankungen
- 12 November 2019
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 161 (S3) , 52-60
Chronisch entzündliche Darmerkrankungen
- 6 October 2009
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 134 (42) , 2132-2136
„TRECID”: TNFα-assoziierte chronisch entzündliche Erkrankungen
In der Pathogenese infektiöser und entzündlicher Erkrankungen nimmt das proinflammatorische Zytokin TNFα eine Schlüsselposition ein. Die Aufklärung seiner zentralen Rolle in der Pathogenese von rheumatoider Arthritis, Spondyloarthritiden, Uveitis, Psoriasis und bei chronisch entzündlichen Darmerkrankungen hat zur Entwicklung von gegen TNFα gerichteten Therapien geführt, bei denen eine Erkrankungs-modifizierende Wirksamkeit beobachtet wird, die über diejenige früherer Therapieoptionen hinausgehen kann. Befunde über das Auftreten weiterer chronisch entzündlicher Autoimmunerkrankungen bei Patienten, die bereits an einer solchen Erkrankung leiden, haben zur Hypothese geführt, dass gemeinsame pathologische Prozesse dieser Zytokin-Dysregulation zugrunde liegen könnten. Entsprechend wurde der Begriff TRECID als Oberbegriff für TNFα-assoziierte chronisch entzündliche Erkrankungen entwickelt. Ärzte verschiedener Fachdisziplinen haben aufgrund dieser Pathophysiologie in den letzten Jahren neue Therapieoptionen mit TNFα-Blockern in ihr Behandlungskonzept integriert. Das TRECID-Konzept kann daher als Modell für eine dynamische, Disziplin-übergreifende Zusammenarbeit auf gemeinsamer pathophysiologischer Basis gelten. The pro-inflammatory cytokine TNF alpha (TNF) has a key position in the pathogenesis of various infectious and inflammatory diseases. Clarification of its pivotal role in the pathogenesis of rheumatoid arthritis, spondyloarthritis, uveitis, psoriasis and inflammatory bowel disease has resulted in the successful development of TNF- blocking therapies, which have disease-modifying properties that exceed the effects of conventional therapeutic options. For this reason data on the concurrence of several chronic inflammatory diseases have led to the hypothesis of common pathogenetic processes of cytokine dysregulation. The acronym TRECID describes this concept of „TNF RElated Chronic Inflammatory Diseases”. Physicians of different specialties have integrated new therapeutic options with TNF-blocking therapies into their strategies for the management of the affected patients. Thus the concept of TRECID can be regarded as a role model for a dynamic, interdisciplinary cooperation based on shared pathophysiological aspects.
- 6 October 2009
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 134 (42) , 2132-2136
„TRECID”: TNFα-assoziierte chronisch entzündliche Erkrankungen
In der Pathogenese infektiöser und entzündlicher Erkrankungen nimmt das proinflammatorische Zytokin TNFα eine Schlüsselposition ein. Die Aufklärung seiner zentralen Rolle in der Pathogenese von rheumatoider Arthritis, Spondyloarthritiden, Uveitis, Psoriasis und bei chronisch entzündlichen Darmerkrankungen hat zur Entwicklung von gegen TNFα gerichteten Therapien geführt, bei denen eine Erkrankungs-modifizierende Wirksamkeit beobachtet wird, die über diejenige früherer Therapieoptionen hinausgehen kann. Befunde über das Auftreten weiterer chronisch entzündlicher Autoimmunerkrankungen bei Patienten, die bereits an einer solchen Erkrankung leiden, haben zur Hypothese geführt, dass gemeinsame pathologische Prozesse dieser Zytokin-Dysregulation zugrunde liegen könnten. Entsprechend wurde der Begriff TRECID als Oberbegriff für TNFα-assoziierte chronisch entzündliche Erkrankungen entwickelt. Ärzte verschiedener Fachdisziplinen haben aufgrund dieser Pathophysiologie in den letzten Jahren neue Therapieoptionen mit TNFα-Blockern in ihr Behandlungskonzept integriert. Das TRECID-Konzept kann daher als Modell für eine dynamische, Disziplin-übergreifende Zusammenarbeit auf gemeinsamer pathophysiologischer Basis gelten. The pro-inflammatory cytokine TNF alpha (TNF) has a key position in the pathogenesis of various infectious and inflammatory diseases. Clarification of its pivotal role in the pathogenesis of rheumatoid arthritis, spondyloarthritis, uveitis, psoriasis and inflammatory bowel disease has resulted in the successful development of TNF- blocking therapies, which have disease-modifying properties that exceed the effects of conventional therapeutic options. For this reason data on the concurrence of several chronic inflammatory diseases have led to the hypothesis of common pathogenetic processes of cytokine dysregulation. The acronym TRECID describes this concept of „TNF RElated Chronic Inflammatory Diseases”. Physicians of different specialties have integrated new therapeutic options with TNF-blocking therapies into their strategies for the management of the affected patients. Thus the concept of TRECID can be regarded as a role model for a dynamic, interdisciplinary cooperation based on shared pathophysiological aspects.
- Open Access
- 1 February 2009
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 3 (1) , S101
P230 - Ethnic differences in the genetic susceptibility to Crohn's disease: functional PPARγ gene variants are not associated with susceptibility to inflammatory bowel disease in the German population
J. Seiderer, J. Glas, J. Diegelmann, C. Markus, S. Pfennig, C. Tillack, M. Jürgens, A. Konrad, M. Wetzke, E. Paschos, H. Török, T. Griga, W. Klein, J.T. Epplen,
- 1 February 2009
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 3 (1) , S101
Open AccessP230 - Ethnic differences in the genetic susceptibility to Crohn's disease: functional PPARγ gene variants are not associated with susceptibility to inflammatory bowel disease in the German population
J. Seiderer, J. Glas, J. Diegelmann, C. Markus, S. Pfennig, C. Tillack, M. Jürgens, A. Konrad, M. Wetzke, E. Paschos, H. Török, T. Griga, W. Klein, J.T. Epplen,
- 9 May 2006
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 38 (5) , 477-482
Low Frequency of Colorectal Dysplasia in Patients with Long-Standing Inflammatory Bowel Disease Colitis: Detection by Fluorescence Endoscopy
Background and Study Aim: Patients with long-standing inflammatory bowel disease (IBD) have an increased risk of developing colonic dysplasias. Dysplastic changes in flat mucosa are likely to be missed by conventional colonoscopy. Endoscopic fluorescence imaging, using 5-aminolevulinic acid (5-ALA) as photosensitizer, has evolved as a new technique to differentiate between normal colonic mucosa and dysplasia. We combined this technique with random biopsies to prospectively evaluate the occurrence of dysplasias in patients with long-standing IBD. Patients and Methods: 52 colonoscopies were performed in 42 consecutive patients (n = 28 with ulcerative colitis, n = 11 with Crohn’s colitis, n = 3 with indeterminate colitis; mean age 43 years, range 21 - 78) with long-standing IBD colitis (median disease duration 14 years, range 3 - 40). All patients were in clinical remission. Patients were examined using both conventional white light and by fluorescence colonoscopy using oral 5-ALA. Four biopsies were taken every 10 cm from mucosa of normal appearance. In addition, macroscopically suspicious and fluorescence-positive areas were biopsied. Results: A total of 688 biopsies of red-fluorescent (n = 20) and nonfluorescent (n = 662) areas of mucosa were taken. Dysplasia was detected histopathologically in only two of the biopsies. These biopsies were taken from two polypoid lesions which were fluorescence-negative. Conclusions: The rate of colonic dysplasia in patients with long-standing IBD colitis may be lower than previously reported.
- 9 May 2006
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 38 (5) , 477-482
Low Frequency of Colorectal Dysplasia in Patients with Long-Standing Inflammatory Bowel Disease Colitis: Detection by Fluorescence Endoscopy
Background and Study Aim: Patients with long-standing inflammatory bowel disease (IBD) have an increased risk of developing colonic dysplasias. Dysplastic changes in flat mucosa are likely to be missed by conventional colonoscopy. Endoscopic fluorescence imaging, using 5-aminolevulinic acid (5-ALA) as photosensitizer, has evolved as a new technique to differentiate between normal colonic mucosa and dysplasia. We combined this technique with random biopsies to prospectively evaluate the occurrence of dysplasias in patients with long-standing IBD. Patients and Methods: 52 colonoscopies were performed in 42 consecutive patients (n = 28 with ulcerative colitis, n = 11 with Crohn’s colitis, n = 3 with indeterminate colitis; mean age 43 years, range 21 - 78) with long-standing IBD colitis (median disease duration 14 years, range 3 - 40). All patients were in clinical remission. Patients were examined using both conventional white light and by fluorescence colonoscopy using oral 5-ALA. Four biopsies were taken every 10 cm from mucosa of normal appearance. In addition, macroscopically suspicious and fluorescence-positive areas were biopsied. Results: A total of 688 biopsies of red-fluorescent (n = 20) and nonfluorescent (n = 662) areas of mucosa were taken. Dysplasia was detected histopathologically in only two of the biopsies. These biopsies were taken from two polypoid lesions which were fluorescence-negative. Conclusions: The rate of colonic dysplasia in patients with long-standing IBD colitis may be lower than previously reported.
- 1 April 2003
- Published by S. Karger AG in Digestion
- Vol. 68 (4) , 209-216
Does Ursodeoxycholic Acid Change the Proliferation of the Colorectal Mucosa?
Background: In animal models ursodeoxycholic acid (UDCA) showed a chemoprotective effect against colon cancer. To explain this, a reduced proliferation of the colorectal mucosal proliferation was suggested. We, therefore, examined the influence of UDCA on the proliferation of normal colorectal mucosa in humans. Methods: Following endoscopic polypectomy, 20 patients with colorectal adenomas were randomized to receive either UDCA (750 mg/day, n = 10, group A) or placebo (n = 10, group B) for 6 months in a double-blinded way. Colorectal biopsies were sampled before and at the end of the medication by total colonoscopy. Colorectal mucosal proliferation was measured by FACScan analysis of propidium iodine labeling. Serum was sampled, and serum bile acids were analyzed by gas chromatography. Results: The proliferation rates at the end of the study were similar in both groups (median 15.4%; range 12.0–20.9 in group A; median 16.0%, 14.0–20.2 in group B, p = 0.41). Serum lithocholic acid levels at the end of the study were significantly higher in group A (1.3 µmol/l, 0.9–1.8) than in group B (0.7 µmol/l, 0–1.7, p < 0.02), whereas serum deoxycholic acid levels were similar in both groups. Conclusions: In this study, UDCA treatment for 6 months does not seem to induce changes in the proliferative behavior of the colorectal mucosa in patients with adenomas. It seems likely that a putative chemopreventive effect of UDCA in humans is not exerted by a reduction of the colorectal proliferation.
- 1 April 2003
- Published by S. Karger AG in Digestion
- Vol. 68 (4) , 209-216
Does Ursodeoxycholic Acid Change the Proliferation of the Colorectal Mucosa?
Background: In animal models ursodeoxycholic acid (UDCA) showed a chemoprotective effect against colon cancer. To explain this, a reduced proliferation of the colorectal mucosal proliferation was suggested. We, therefore, examined the influence of UDCA on the proliferation of normal colorectal mucosa in humans. Methods: Following endoscopic polypectomy, 20 patients with colorectal adenomas were randomized to receive either UDCA (750 mg/day, n = 10, group A) or placebo (n = 10, group B) for 6 months in a double-blinded way. Colorectal biopsies were sampled before and at the end of the medication by total colonoscopy. Colorectal mucosal proliferation was measured by FACScan analysis of propidium iodine labeling. Serum was sampled, and serum bile acids were analyzed by gas chromatography. Results: The proliferation rates at the end of the study were similar in both groups (median 15.4%; range 12.0–20.9 in group A; median 16.0%, 14.0–20.2 in group B, p = 0.41). Serum lithocholic acid levels at the end of the study were significantly higher in group A (1.3 µmol/l, 0.9–1.8) than in group B (0.7 µmol/l, 0–1.7, p < 0.02), whereas serum deoxycholic acid levels were similar in both groups. Conclusions: In this study, UDCA treatment for 6 months does not seem to induce changes in the proliferative behavior of the colorectal mucosa in patients with adenomas. It seems likely that a putative chemopreventive effect of UDCA in humans is not exerted by a reduction of the colorectal proliferation.
- 1 January 2003
- Published by Springer Nature in Der Radiologe
- Vol. 43 (1) , 1-8
Chronisch entzündliche Darmerkrankungen – Kritische Diskussion von Ätiologie, Pathogenese, Diagnostik und Therapie
Zielsetzung. Die chronisch entzündlichen Darmerkrankungen (CED) Morbus Crohn und Colitis ulcerosa befallen ca. jeden 500.Menschen. Obwohl sich, angetrieben durch therapeutische Erfolge der Zytokinforschung, immer mehr medizinische Einrichtungen mit Fragestellungen rund um die CED beschäftigen, stellen diese Erkrankungen für Patient und Arzt immer noch eine lebenslange Herausforderung dar.Die enge interdisziplinäre Zusammenarbeit zwischen Gastroenterologie, Radiologie und Chirurgie ist entscheidend für ein effizientes Diagnose- und Therapiekonzept, dessen Grundlagen wir in unserer Übersichtsarbeit erläutern wollen. Methodik. Aus der Sicht des den Patienten betreuenden Gastroenterologen werden, basierend auf aktuellen Publikationen und Erfahrungswerten einer CED-Klinik, Aspekte aus Ätiologie,Pathogenese,Diagnostik und Therapie der CED dargestellt. Ergebnisse. Eine genetisch beeinflusste, überschießende und anhaltende Immunreaktion gegen die eigene Darmflora scheint eine der wichtigsten Ursachen dieser Erkrankungen zu sein.Auch Umwelteinflüsse sind von Belang.So wurde z.B.lange Zeit der Einfluss des Zigarettenrauchens beim Morbus Crohn als ungünstig eingeschätzt, nun zeigt sich sogar, dass Rauchen einen eindeutigen Risikofaktor in Genese und Unterhaltung dieser Erkrankung darstellt.Da die CED und insbesondere der Morbus Crohn als systemische Erkrankungen betrachtet werden müssen, setzen therapeutische Überlegungen eine genaue Kenntnis des Organbefalls voraus.So kann z.B.durch den Einsatz der MRT-Enteroklysmatechnik eine strahlungsarme Untersuchung derjenigen Teile des Verdauungstrakts erreicht werden, die bisher einer routinemäßigen Inspektion nicht zugänglich waren,wie z.B.das untere Jejunum und das obere Ileum. Therapeutisch scheint es zu einem Paradigmenwechsel zu kommen: Patienten werden nicht mehr erst dann behandelt,wenn die Symptome unerträglich geworden sind, sondern frühzeitig in ein therapeutisches Gesamtkonzept integriert, das sich an Ort und Ausmaß des Befalls, an den Möglichkeiten des Patienten und auch des betreuenden Umfeldes orientiert.Außerdem etablieren sich die immunsuppressiv wirksamen Purinanaloga wie Azathioprin und Mercaptopurin als zentrales Medikationskonzept der CED. Diskussion. Es ist absehbar, dass eine spezifisch auf das Befallsmuster des Patienten abgestimmte Therapie das aussichtsreichste Behandlungskonzept darstellt, das sich nicht mehr an strengen Schemata orientiert. Die neuen endoskopischen und radiologischen Verfahren bilden hierfür die Grundlage. Aims. Crohn's disease and ulcerative colitis are the most frequent inflammatory bowel diseases (IBD) with a prevalence of approximately one out of 500.Cytokine research opened new and potent treatment options and thus stimulated clinical and basic research.However, the IBD still remain a challenge for patients and physicians,demanding close cooperation between gastroenterologists,radiologists and surgeons.The basic understanding of IBD,which is necessary for efficient diagnostic and therapeutic concepts is reviewed. Methods. Based upon recent publications and our clinical experience we discussaspectsofetiology,pathogenesis,diagnostics,and therapy of Crohn's disease and ulcerative colitis. Results. A genetically influenced, exaggerated and sustained immune response against the own gut flora seems to be one of the most important factors in the pathogenesis of IBD.Not less important are environmental influences.For instance, cigarette smoking had been judged to have some negative influence on the natural course of Crohn's disease.Now,however, recent studies show that smoking is even a significant independent risk factor in the pathogenesis of IBD. Since IBD and especially Crohn's disease can effect the whole body, detailed analysis of inflammatory organ involvement is necessary before therapy.For instance, the MRIenteroclysis technique adds a necessary diagnostic tool for the exploration of those parts of the small bowel that cannot been reached by routine endoscopy like the upper ileum and the lower jejunum. In terms of therapy, a change of paradigms can be observed: patients will no longer be treated only when symptoms arise, but will early be integrated into a therapeutic concept, which is determined by site and extent of the disease and adapted to the abilities and needs of the patient.Furthermore,immunosuppressive agents like azathioprine and 6-mercaptopurine will establish as central concept in the medical treatment of IBD. Discussion. IBD-therapy should rather be adapted to the patient's individual inflammatory pattern than be oriented to schematic treatment rules.New endoscopic and radiologic techniques provide the necessary diagnostic tools.
- 1 January 2003
- Published by Springer Nature in Der Radiologe
- Vol. 43 (1) , 1-8
Chronisch entzündliche Darmerkrankungen – Kritische Diskussion von Ätiologie, Pathogenese, Diagnostik und Therapie
Zielsetzung. Die chronisch entzündlichen Darmerkrankungen (CED) Morbus Crohn und Colitis ulcerosa befallen ca. jeden 500.Menschen. Obwohl sich, angetrieben durch therapeutische Erfolge der Zytokinforschung, immer mehr medizinische Einrichtungen mit Fragestellungen rund um die CED beschäftigen, stellen diese Erkrankungen für Patient und Arzt immer noch eine lebenslange Herausforderung dar.Die enge interdisziplinäre Zusammenarbeit zwischen Gastroenterologie, Radiologie und Chirurgie ist entscheidend für ein effizientes Diagnose- und Therapiekonzept, dessen Grundlagen wir in unserer Übersichtsarbeit erläutern wollen. Methodik. Aus der Sicht des den Patienten betreuenden Gastroenterologen werden, basierend auf aktuellen Publikationen und Erfahrungswerten einer CED-Klinik, Aspekte aus Ätiologie,Pathogenese,Diagnostik und Therapie der CED dargestellt. Ergebnisse. Eine genetisch beeinflusste, überschießende und anhaltende Immunreaktion gegen die eigene Darmflora scheint eine der wichtigsten Ursachen dieser Erkrankungen zu sein.Auch Umwelteinflüsse sind von Belang.So wurde z.B.lange Zeit der Einfluss des Zigarettenrauchens beim Morbus Crohn als ungünstig eingeschätzt, nun zeigt sich sogar, dass Rauchen einen eindeutigen Risikofaktor in Genese und Unterhaltung dieser Erkrankung darstellt.Da die CED und insbesondere der Morbus Crohn als systemische Erkrankungen betrachtet werden müssen, setzen therapeutische Überlegungen eine genaue Kenntnis des Organbefalls voraus.So kann z.B.durch den Einsatz der MRT-Enteroklysmatechnik eine strahlungsarme Untersuchung derjenigen Teile des Verdauungstrakts erreicht werden, die bisher einer routinemäßigen Inspektion nicht zugänglich waren,wie z.B.das untere Jejunum und das obere Ileum. Therapeutisch scheint es zu einem Paradigmenwechsel zu kommen: Patienten werden nicht mehr erst dann behandelt,wenn die Symptome unerträglich geworden sind, sondern frühzeitig in ein therapeutisches Gesamtkonzept integriert, das sich an Ort und Ausmaß des Befalls, an den Möglichkeiten des Patienten und auch des betreuenden Umfeldes orientiert.Außerdem etablieren sich die immunsuppressiv wirksamen Purinanaloga wie Azathioprin und Mercaptopurin als zentrales Medikationskonzept der CED. Diskussion. Es ist absehbar, dass eine spezifisch auf das Befallsmuster des Patienten abgestimmte Therapie das aussichtsreichste Behandlungskonzept darstellt, das sich nicht mehr an strengen Schemata orientiert. Die neuen endoskopischen und radiologischen Verfahren bilden hierfür die Grundlage. Aims. Crohn's disease and ulcerative colitis are the most frequent inflammatory bowel diseases (IBD) with a prevalence of approximately one out of 500.Cytokine research opened new and potent treatment options and thus stimulated clinical and basic research.However, the IBD still remain a challenge for patients and physicians,demanding close cooperation between gastroenterologists,radiologists and surgeons.The basic understanding of IBD,which is necessary for efficient diagnostic and therapeutic concepts is reviewed. Methods. Based upon recent publications and our clinical experience we discussaspectsofetiology,pathogenesis,diagnostics,and therapy of Crohn's disease and ulcerative colitis. Results. A genetically influenced, exaggerated and sustained immune response against the own gut flora seems to be one of the most important factors in the pathogenesis of IBD.Not less important are environmental influences.For instance, cigarette smoking had been judged to have some negative influence on the natural course of Crohn's disease.Now,however, recent studies show that smoking is even a significant independent risk factor in the pathogenesis of IBD. Since IBD and especially Crohn's disease can effect the whole body, detailed analysis of inflammatory organ involvement is necessary before therapy.For instance, the MRIenteroclysis technique adds a necessary diagnostic tool for the exploration of those parts of the small bowel that cannot been reached by routine endoscopy like the upper ileum and the lower jejunum. In terms of therapy, a change of paradigms can be observed: patients will no longer be treated only when symptoms arise, but will early be integrated into a therapeutic concept, which is determined by site and extent of the disease and adapted to the abilities and needs of the patient.Furthermore,immunosuppressive agents like azathioprine and 6-mercaptopurine will establish as central concept in the medical treatment of IBD. Discussion. IBD-therapy should rather be adapted to the patient's individual inflammatory pattern than be oriented to schematic treatment rules.New endoscopic and radiologic techniques provide the necessary diagnostic tools.